DDR-MYCN-NB

The DNA damage response pathway in MYCN amplified neuroblastoma

Coordinatore	more  Organization address address: Im Neuenheimer Feld 280 city: HEIDELBERG postcode: 69120 contact info Titolo: Dr. Nome: Ina Cognome: Krischek Email: send email Telefono: +49 6221 422700
Nazionalità Coordinatore	Non specificata
Totale costo	169˙363 €
EC contributo	0 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-01-01   -   2013-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	DEUTSCHES KREBSFORSCHUNGSZENTRUM  Organization address address: Im Neuenheimer Feld 280 city: HEIDELBERG postcode: 69120 contact info Titolo: Dr. Nome: Ina Cognome: Krischek Email: send email Telefono: +49 6221 422700	DE (HEIDELBERG)	coordinator	169˙363.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Accurate replication of the genome is very important in cells to prevent the propagation of mutations which cause tumour development. After DNA damage, normal non-cancerous cells arrest the cell cycle in G1 to prevent cell growth until DNA damage is repaired or, if levels of damage are high, cells undergo programmed cell death. Stress responses leading to a DNA damage response stem from different sources and activate distinct pathways. However, they converge on the same components of the cell cycle machinery in the G1 phase of the cell cycle, namely the cyclin dependent kinases. To investigate the mechanisms that MYC proteins affect the G1 checkpoint, we propose to use neuroblastoma with deregulated MYCN expression as a paradigm to examine the mechanisms that MYC proteins act on the DNA damage response pathway. This DNA damage pathway is complex and acts in two main stages, an early inhibition of cyclin dependent kinase inhibitors by redistribution of p21WAF1 and a more sustained transcriptional response is mediated by p53. To appreciate the complexity of the DNA damage response pathway experimental data will be integrated with computer based mathematical modelling techniques to build a model of this pathway and how it is affected by deregulated MYCN expression. Understanding the effect of MYC proteins on the DNA damage pathway is essential for future advances in cancer treatments, as a large number of current chemotherapeutics are DNA damaging agents. This project will provide a general model for all cancer types driven by MYC proteins, it will also provide important prognostic indicators and new drug targets for the treatment of neuroblastoma- a cancer that accounts for 8% of all childhood malignancies where patients diagnosed with high risk neuroblastoma have a 5-year overall survival of only ~60%.'